MTNB

BTIG analyst Robert Hazlett maintained a Buy rating on Matinas BioPharma (MTNB – Research Report) on March 9 and set a price target of $3.00. The company's shares closed last Friday at $0.70. According to TipRanks.com, Hazlett is a 3-star analyst with an average return of 3.8% and a 34.6% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Eiger Biopharmaceuticals, and TRACON Pharmaceuticals. Currently, the analyst consensus on Matinas BioPharma is a Strong Buy with an average price target of $3.00, implying a 413.3% upside from current levels. In a report issued on March 9, H.C.
https://www.tipranks.com/news/blurbs/btig-maintains-their-buy-rating-on-matinas-biopharma-mtnb?utm_source=advfn.com&utm_medium=referral